Brain-computer interfaces and the future of neural engineering with Dr. Benjamin Rapoport | E1682

Episode Summary

Executive Summary: Precision Neuroscience co-founder Benjamin Rapaport describes developing a high-bandwidth brain-computer interface using a thin, removable electrode array that rests on the brain rather than penetrating it. He traces the field’s progress to advances in microfabrication, computing, and neural decoding, and explains Precision’s focus on safety, clinical translation, and a temporary diagnostic device as an initial step toward future therapeutic applications for paralysis and speech impairment.

Main Topics: How brain-computer interfaces work: Neurons communicate through electrical impulses. An interface records or stimulates those signals, while computational systems learn to decode each person’s neural patterns and translate them into computer commands. Technological roots of the field: Rapaport connects modern BCIs to standardized, microfabricated electrode arrays developed around the late 1980s and early 1990s, followed by advances in computing and signal-processing that made larger-scale neural decoding practical. Precision’s surface-array design: Precision’s Layer 7 interface is a thin array of many small electrodes placed on the brain’s surface. Unlike penetrating electrodes, it is designed to record and stimulate at high resolution while being removable without damaging brain tissue. Clinical rollout and regulatory strategy: The company plans an initial temporary device for clinical and diagnostic uses, including epilepsy-related applications. Rapaport says this approach may fit the FDA’s 510(k) pathway and provide clinical experience before development of permanent interfaces. Commercialization and industry ecosystem: Rapaport argues that moving research from academia into companies can provide the engineering, funding, manufacturing, and regulatory capabilities needed for clinical deployment. He compares neural interfaces’ transition to industry with the genomics shift of the early 2000s. Potential impact and economics: Higher-resolution interfaces may help restore communication or movement for people with paralysis and speech impairment. Rapaport argues that greater independence and return-to-work opportunities could justify higher device costs, while software updates and shared learning from patient data may shape the business model.

Key Arguments: High-bandwidth neural interfaces became feasible through the convergence of reproducible microfabricated electrodes, improved computational power, and algorithms capable of adapting to individual differences in neural signals. A surface-based interface could offer a safety advantage over electrodes that penetrate brain tissue, while still placing sensors close enough to capture high-resolution signals; fully external scalp interfaces cannot provide comparable spatial and temporal resolution. Precision’s removable first-generation system is intended to reduce risk and support an initial diagnostic application, while generating practical clinical experience that can inform later therapeutic and potentially permanent devices. No single neural interface is likely to serve every use case; different electrode designs can address different clinical needs and coexist within a broader field. Commercial development is needed to convert academic results into reliable, manufacturable, regulated medical products, though it creates a persistent tension with the openness and research capacity of academia. The economic case for neural interfaces may rest not only on device costs but also on improved independence and potential workforce participation; future software upgrades may add functionality over time.

Data Points: Precision Neuroscience funding raised: $53 million - The host states that Precision has raised this amount to date. People in the United States living with some form of paralysis: Millions - Rapaport gives this as a broad estimate, including paralysis related to spinal cord injury and other disorders. Utah Electrode Array scale: Approximately 100 electrodes; described as about 96 or 100 - The microfabricated array helped standardize neural recording and enable simultaneous measurements. Early microfabricated electrode-array development: Late 1980s to early 1990s - Rapaport identifies this period as a turning point in neuroscience electrode manufacturing. Neurons per millimeter (illustrative estimate): About 20 neuron cell bodies side by side - Rapaport uses this analogy to convey the small scale of neurons. Target timeframe for Precision’s initial system: 12 to 18 months - Rapaport describes this as the expected timeframe for pursuing an early high-bandwidth clinical system. FDA submission timing: That year, as stated in the interview - Rapaport says Precision was getting ready for FDA submission; the transcript does not specify a calendar year. Potential cost relative to current implantable neural devices: More expensive, but probably not 10 times as expensive - Rapaport offers a qualitative estimate, not a specific price or finalized reimbursement model.

Pivotal Quotes: "So what A precision system is doing is to get as close to the brain as you can without damaging it." — Benjamin Rapaport: This summarizes Precision’s central design principle: high-resolution access while avoiding tissue penetration. "Every patient should be helping every patient that comes after them." — Benjamin Rapaport: Rapaport describes how patient data and machine learning could improve care for future users. "The science fiction of the prior generation inspires the next generation to try to turn science fiction into fact." — Benjamin Rapaport: He reflects on the long arc from imagined brain interfaces to practical engineering and clinical development.

Implications: If clinical testing confirms safety and useful performance, surface-based high-bandwidth interfaces could expand access to neural diagnostics and assistive technologies. Progress will depend on evidence, FDA review, scalable manufacturing, reimbursement, and responsible use of patient data.